Circadian Rhythm As a Key Player in Cancer Progression As Well As a Therapeutic Target in -positive Advanced Gastric Cancer Treatment
Overview
Authors
Affiliations
Gastric cancer is one of the most common cancer types with less than one year prognosis in metastatic disease, which poses a huge disease burden. One of the key players in poor prognosis is human epidermal growth factor receptor 2 (), which also contributes to the pathogenesis of -positive advanced gastric cancer. Trastuzumab is used as first-line chemotherapy that targets the expression of , however, trastuzumab resistance is an inevitable major problem. To overcome this problem, readjustment of the circadian system may play a crucial role, as dysregulation in the expression of circadian clock genes has been observed in tumors. Therefore, pharmacological modulation of clock components can be considered for better efficacy of trastuzumab. In this review, we discuss the association of circadian clock with cancer progression, development, and treatment. Metformin-based chronotherapy can disrupt BMAL1-CLOCK-PER1-HK2 axis, thereby affecting glycolysis oscillation to overcome trastuzumab resistance in HER2-positive advanced gastric cancer.
Evolving Landscape of HER2-Targeted Therapies for Gastric Cancer Patients.
He L, Liu B, Wang Z, Han Q, Chen H Curr Treat Options Oncol. 2025; .
PMID: 40056280 DOI: 10.1007/s11864-025-01300-0.
Wang J, Shao F, Yu Q, Ye L, Wusiman D, Wu R Research (Wash D C). 2025; 8:0612.
PMID: 40046513 PMC: 11880593. DOI: 10.34133/research.0612.
Fu C, Sun L, Feng C, Zhou T, Bi Y Front Oncol. 2025; 15:1464578.
PMID: 40040723 PMC: 11876053. DOI: 10.3389/fonc.2025.1464578.
Hu J, Bu W, Ding Y, Li X, Zhang B, Shen B Immun Inflamm Dis. 2025; 13(2):e70154.
PMID: 39917999 PMC: 11803458. DOI: 10.1002/iid3.70154.
Circadian rhythm disruption and endocrine-related tumors.
Savvidis C, Kallistrou E, Kouroglou E, Dionysopoulou S, Gavriiloglou G, Ragia D World J Clin Oncol. 2024; 15(7):818-834.
PMID: 39071458 PMC: 11271730. DOI: 10.5306/wjco.v15.i7.818.